Effects of ursodeoxycholic acid on statin-induced impaired glucose tolerance: study protocol for a randomized controlled trial.
Yue Yu, Jie Zheng, Jianqing She...
https://pubmed.ncbi.nlm.nih.gov/42521308/Actively Recruiting
Led by First Affiliated Hospital Xi'an Jiaotong University · Updated on 2026-06-30
128
Participants Needed
2
Research Sites
28 weeks
Total Duration
Researchers are evaluating whether Ursodeoxycholic acid UDCA can prevent glucose intolerance in adults with hyperlipidemia who are taking statin medications. The study also aims to assess the safety of UDCA and examine if it reduces other adverse events in patients using oral statins. This is a randomized controlled clinical trial conducted by the First Affiliated Hospital Xian Jiaotong University. Participants will be randomly assigned to one of two groups one receiving UDCA 500 mg daily combined with Atorvastatin, and the other receiving a placebo combined with Atorvastatin. Treatment lasts for 6 months, with follow-up visits on day 40, day 110, and day 180. The trial uses a double-blind method to compare the effects of UDCA and placebo when taken alongside statins. During the study, participants will have their blood sugar control measured using HbA1c at 6 months, along with fasting blood glucose, islet concentration, blood lipid levels, and body composition analysis including fat and muscle mass. These assessments help researchers understand how UDCA might affect glucose tolerance and other metabolic factors. Safety and adherence will be monitored throughout the 6-month treatment period.
CONDITIONS
Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance
Y
Yue Yu
Y
Yue Wu, Professor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
First Affiliated Hospital Xi'an Jiaotong University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 6 months
Participants receive daily Ursodeoxycholic acid or placebo combined with Atorvastatin for 6 months.
Follow-up visits on day 40, day 110, and day 180
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Yue Yu, Jie Zheng, Jianqing She...
https://pubmed.ncbi.nlm.nih.gov/42521308/First Affiliated Hospital Xi'an Jiaotong University
Lead Sponsor